La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Seelos Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Seelos Therapeutics' est Raj Mehra, nommé en Jan2019, a un mandat de 5.58 ans. La rémunération annuelle totale est $ 1.73M, composée du salaire de 34% et des bonus 66%, y compris les actions et options de la société. détient directement 0.81% des actions de la société, d'une valeur de $ 20.76K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.3 ans et 5.6 ans.

Informations clés

Raj Mehra

Directeur général

US$1.7m

Rémunération totale

Pourcentage du salaire du PDG	34.0%
Durée du mandat du directeur général	5.7yrs
Propriété du PDG	0.3%
Durée moyenne d'occupation des postes de direction	4.3yrs
Durée moyenne du mandat des membres du conseil d'administration	5.7yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Raj Mehra a-t-elle évolué par rapport aux bénéfices de Seelos Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$4m
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$2m	US$587k	-US$38m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$2m	US$562k	-US$74m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$73m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$16m	US$523k	-US$66m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$4m	US$475k	-US$19m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$709k	US$438k	-US$51m

Rémunération vs marché: La rémunération totale de Raj ($USD 1.73M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Raj a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Raj Mehra (64 yo)

5.7yrs

Titularisation

US$1,726,476

Compensation

Dr. Raj Mehra, Ph D., J.D., was an Independent Director at Larkspur Health Acquisition Corp. since July 2021 and serves as its Director. He was Chairman of Seelos Therapeutics, Inc & serves as Chief Execut...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Raj Mehra	CEO, Founder	5.7yrs	US$1.73m	0.33% $ 5.6k
Michael Golembiewski	Chief Financial Officer	3yrs	US$846.67k	0.16% $ 2.6k
Anthony Marciano	Chief Communications Officer	5.7yrs	pas de données	pas de données
Gopal Krishna	Head of Manufacturing & Technical Operations	no data	pas de données	pas de données
Tim Whitaker	Chief Medical Officer	no data	pas de données	pas de données
Karen Fusaro	Senior VP & Head of Clinical Operations	1.8yrs	pas de données	pas de données

4.3yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de SEEL est considérée comme expérimentée (ancienneté moyenne 4.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Raj Mehra	CEO, Founder	5.7yrs	US$1.73m	0.33% $ 5.6k
Margaret Dalesandro	Independent Director	3yrs	US$89.72k	0.0021% $ 35.0
Richard Pascoe	Independent Chairman	11.5yrs	US$87.72k	0.00023% $ 3.9
Brian Lian	Independent Director	5.7yrs	US$105.22k	0% $ 0

5.7yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de SEEL sont considérés comme expérimentés (ancienneté moyenne 5.6 ans).

Seelos Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

Chief Financial Officer recently bought US$100k worth of stock

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

High number of new and inexperienced directors

Recent updates

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Price target decreased to US$8.58

We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely

Seelos: Superior Data, But Early Stage

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

New 90-day high: US$4.75

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

New 90-day high: US$3.57

Seelos announces issuance of a patent for trehalose (SLS-005) in Australia

New 90-day high: US$2.17